Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16017895 | 0.86 | HTR2C (0.49) | ADRA2AADRA1AMAPTBLMHTR2C | |
| SCHEMBL16017786 | 0.86 | ADRA2A (0.43) | ADRA2AADRA1AMAPTBLMHTR2C | |
| SCHEMBL10031825 | 0.84 | HTR2C (0.46) | ADRA2AADRA1AMAPTBLMHTR2C | |
| SCHEMBL27631198 | 0.83 | CYP1A2 (0.47) | ADRA2AADRA1AMAPTBLMHTR2C | |
| SCHEMBL16017828 | 0.83 | ADRA2A (0.41) | ADRA2AADRA1AMAPTBLMHTR2C | |
| SCHEMBL16017794 | 0.82 | ADRA2A (0.37) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL16017798 | 0.82 | ADRA2A (0.37) | ADRA2AADRA1AMAPTBLMHTR2C | |
| SCHEMBL16017780 | 0.81 | DGKA (0.50) | ADRA2AADRA1AMAPTBLMHTR2C | |
| SCHEMBL19265611 | 0.80 | HTR2C (0.40) | ADRA2AADRA1AMAPTBLMHTR2C | |
| SCHEMBL16017779 | 0.79 | ADRA2A (0.43) | ADRA2AADRA1AMAPTBLMHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256660-A1 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256660-A1 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS | CYP21A2, CYP17A1, CYP46A1 | ADRA2A 4577/4885ADRA1A 3774/4885MAPT 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.